Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
Yu Xuan
YX
Koo
Daniel S W
DS
Tan
Bee Huat
BH
Tan
Richard
R
Quek
Miriam
M
Tao
Soon Thye
ST
Lim
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D006509:Hepatitis B / Q000517:prevention & control; D006512:Hepatitis B Core Antigens / Q000378:metabolism*; D006514:Hepatitis B Surface Antigens / Q000378:metabolism*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D011239:Prednisolone / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone